Company Filing History:
Years Active: 2017-2018
Title: Michael Cappillino: Innovator in Phage Technologies
Introduction
Michael Cappillino, an accomplished inventor based in Reading, MA, has made significant contributions to the field of microbial detection through his innovative work with recombinant phages. With a notable portfolio of two patents, Cappillino’s inventions reflect both creativity and scientific rigor.
Latest Patents
Cappillino's most recent patents include advancements in the field of recombinant phages. The first patent focuses on codon optimized recombinant phage and methods for utilizing them to detect one or more target microbes. This composition integrates a capsid protein sequence, a ribosome binding site, and a codon-optimized marker to enhance the efficacy of detection. Additionally, it encompasses an aqueous solution that amplifies the ability to recognize marker expression upon phage infection. His second patent elaborates on a phage-based bacterial detection assay, introducing methods to assess target bacteria using a phage capable of infecting sets of specified bacteria, which includes a heterologous nucleic acid sequence encoding a marker.
Career Highlights
Throughout his career, Michael Cappillino has been associated with notable organizations such as Phage Diagnostics, Inc. and the Institute for Environmental Health. His work in these companies has laid the groundwork for his innovative contributions to microbial detection technologies.
Collaborations
Cappillino has worked alongside esteemed colleagues such as Michael Koeris and Robert Patrick Shivers. Their collaboration has likely fostered a dynamic exchange of ideas and expertise, further propelling advancements in their shared field of study.
Conclusion
Michael Cappillino stands out as a prominent inventor, whose work with recombinant phages is transformative in the realm of microbial detection. With his significant patents and collaborative efforts, he continues to push the boundaries of innovation, making valuable contributions to the scientific community.